ES2880089T3 - Combinaciones de irinotecán liposomal, 5-FU y leucovorina para el tratamiento del cáncer pancreático - Google Patents
Combinaciones de irinotecán liposomal, 5-FU y leucovorina para el tratamiento del cáncer pancreático Download PDFInfo
- Publication number
- ES2880089T3 ES2880089T3 ES17169098T ES17169098T ES2880089T3 ES 2880089 T3 ES2880089 T3 ES 2880089T3 ES 17169098 T ES17169098 T ES 17169098T ES 17169098 T ES17169098 T ES 17169098T ES 2880089 T3 ES2880089 T3 ES 2880089T3
- Authority
- ES
- Spain
- Prior art keywords
- irinotecan
- leucovorin
- patient
- dose
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004768 irinotecan Drugs 0.000 title claims abstract description 165
- 238000011282 treatment Methods 0.000 title claims abstract description 124
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title claims abstract description 112
- 229960002949 fluorouracil Drugs 0.000 title claims abstract description 112
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 235000008191 folinic acid Nutrition 0.000 title claims abstract description 96
- 239000011672 folinic acid Substances 0.000 title claims abstract description 96
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 title claims abstract description 96
- 229960001691 leucovorin Drugs 0.000 title claims abstract description 96
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 56
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 52
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 43
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 43
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title claims abstract 5
- 239000002502 liposome Substances 0.000 claims abstract description 51
- 238000002347 injection Methods 0.000 claims abstract description 35
- 239000007924 injection Substances 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 31
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 26
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 26
- -1 irinotecan sucrose octasulfate salt Chemical class 0.000 claims abstract description 22
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical class OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims abstract description 12
- 238000011260 co-administration Methods 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 107
- 239000003814 drug Substances 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 34
- 108700028369 Alleles Proteins 0.000 claims description 32
- 229940079593 drug Drugs 0.000 claims description 29
- 238000002560 therapeutic procedure Methods 0.000 claims description 28
- 230000001988 toxicity Effects 0.000 claims description 27
- 231100000419 toxicity Toxicity 0.000 claims description 27
- 230000001965 increasing effect Effects 0.000 claims description 21
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 13
- 230000001394 metastastic effect Effects 0.000 claims description 11
- 208000009956 adenocarcinoma Diseases 0.000 claims description 9
- 229960003957 dexamethasone Drugs 0.000 claims description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 9
- 206010027476 Metastases Diseases 0.000 claims description 8
- 239000002111 antiemetic agent Substances 0.000 claims description 7
- 230000003474 anti-emetic effect Effects 0.000 claims description 6
- 230000009401 metastasis Effects 0.000 claims description 6
- 208000007569 Giant Cell Tumors Diseases 0.000 claims description 5
- 208000006336 acinar cell carcinoma Diseases 0.000 claims description 5
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 5
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims description 5
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 230000009826 neoplastic cell growth Effects 0.000 claims description 4
- 208000002820 pancreatoblastoma Diseases 0.000 claims description 2
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 abstract description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 5
- 239000005720 sucrose Substances 0.000 abstract description 5
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 152
- PMZSPINGJVBHAT-DJBCQDJXSA-N irinotecan sucrosofate Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1.OS(=O)(=O)O[C@H]1[C@@H](OS(O)(=O)=O)[C@@H](COS(=O)(=O)O)O[C@@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 PMZSPINGJVBHAT-DJBCQDJXSA-N 0.000 description 102
- 238000001802 infusion Methods 0.000 description 40
- 230000004044 response Effects 0.000 description 40
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 description 37
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 25
- 206010012735 Diarrhoea Diseases 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 230000004083 survival effect Effects 0.000 description 24
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 21
- 201000010099 disease Diseases 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 208000004235 neutropenia Diseases 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 230000009467 reduction Effects 0.000 description 16
- 230000002411 adverse Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 14
- 230000034994 death Effects 0.000 description 13
- 231100000517 death Toxicity 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 206010061818 Disease progression Diseases 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 230000005750 disease progression Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 230000006872 improvement Effects 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 230000003111 delayed effect Effects 0.000 description 8
- 231100000226 haematotoxicity Toxicity 0.000 description 8
- 208000037821 progressive disease Diseases 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 108700012439 CA9 Proteins 0.000 description 7
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 230000007954 hypoxia Effects 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 102000003960 Ligases Human genes 0.000 description 6
- 108090000364 Ligases Proteins 0.000 description 6
- 108010022394 Threonine synthase Proteins 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 102000004419 dihydrofolate reductase Human genes 0.000 description 6
- 229940014144 folate Drugs 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 6
- 239000011724 folic acid Substances 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 230000023611 glucuronidation Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000009097 single-agent therapy Methods 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000002633 Febrile Neutropenia Diseases 0.000 description 5
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 description 5
- 206010066901 Treatment failure Diseases 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000000118 anti-neoplastic effect Effects 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000001713 cholinergic effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000000439 tumor marker Substances 0.000 description 5
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 4
- 229930003347 Atropine Natural products 0.000 description 4
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 4
- 229960000396 atropine Drugs 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 208000008384 ileus Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 229940008678 levoleucovorin Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 150000003230 pyrimidines Chemical class 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 3
- FFKUHGONCHRHPE-UHFFFAOYSA-N 5-methyl-1h-pyrimidine-2,4-dione;7h-purin-6-amine Chemical compound CC1=CNC(=O)NC1=O.NC1=NC=NC2=C1NC=N2 FFKUHGONCHRHPE-UHFFFAOYSA-N 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 206010014418 Electrolyte imbalance Diseases 0.000 description 3
- 206010071602 Genetic polymorphism Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
- 108010016076 Octreotide Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 229940125683 antiemetic agent Drugs 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 229960001433 erlotinib Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229960002700 octreotide Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 2
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 208000009139 Gilbert Disease Diseases 0.000 description 2
- 208000022412 Gilbert syndrome Diseases 0.000 description 2
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 2
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 208000037844 advanced solid tumor Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 229940088954 camptosar Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000012829 chemotherapy agent Substances 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000011970 concomitant therapy Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 208000002445 cystadenocarcinoma Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000008355 dextrose injection Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000009114 investigational therapy Methods 0.000 description 2
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 2
- 208000034415 irinotecan toxicity Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 229960001571 loperamide Drugs 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 239000003790 pyrimidine antagonist Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010206 sensitivity analysis Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000006276 transfer reaction Methods 0.000 description 2
- 238000013520 translational research Methods 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008674 Cholinergic syndrome Diseases 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 108010066455 Dihydrouracil Dehydrogenase (NADP) Proteins 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 101000902632 Homo sapiens Dihydropyrimidine dehydrogenase [NADP(+)] Proteins 0.000 description 1
- 101000841498 Homo sapiens UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000011789 NOD SCID mouse Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- LREILSUKWDDXJX-UHFFFAOYSA-N S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC Chemical compound S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC.C(C)[NH+](CC)CC LREILSUKWDDXJX-UHFFFAOYSA-N 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102100033782 UDP-galactose translocator Human genes 0.000 description 1
- 101710148271 UDP-glucose:glycoprotein glucosyltransferase 1 Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- GOHCTCOGYKAJLZ-UHFFFAOYSA-N ctep Chemical compound CC=1N(C=2C=CC(OC(F)(F)F)=CC=2)C(C)=NC=1C#CC1=CC=NC(Cl)=C1 GOHCTCOGYKAJLZ-UHFFFAOYSA-N 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940041216 diphenhydramine hydrochloride 50 mg Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940078646 other antiemetics in atc Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000011375 palliative radiation therapy Methods 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000011518 platinum-based chemotherapy Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659211P | 2012-06-13 | 2012-06-13 | |
| US201361784382P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2880089T3 true ES2880089T3 (es) | 2021-11-23 |
Family
ID=48692681
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17169098T Active ES2880089T3 (es) | 2012-06-13 | 2013-06-12 | Combinaciones de irinotecán liposomal, 5-FU y leucovorina para el tratamiento del cáncer pancreático |
| ES13731230.2T Active ES2632915T3 (es) | 2012-06-13 | 2013-06-12 | Métodos para tratar el cáncer pancreático utilizando terapias combinadas que comprende liposomal irinotecán |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13731230.2T Active ES2632915T3 (es) | 2012-06-13 | 2013-06-12 | Métodos para tratar el cáncer pancreático utilizando terapias combinadas que comprende liposomal irinotecán |
Country Status (21)
| Country | Link |
|---|---|
| US (10) | US9452162B2 (enExample) |
| EP (3) | EP3266456B1 (enExample) |
| JP (3) | JP6310911B2 (enExample) |
| KR (3) | KR101776808B1 (enExample) |
| CN (2) | CN104717961A (enExample) |
| AU (3) | AU2013202947B2 (enExample) |
| BR (1) | BR112014031088A8 (enExample) |
| CA (1) | CA2875824C (enExample) |
| DK (2) | DK3266456T3 (enExample) |
| ES (2) | ES2880089T3 (enExample) |
| IL (3) | IL294886A (enExample) |
| IN (1) | IN2014DN11099A (enExample) |
| MX (1) | MX376937B (enExample) |
| NZ (1) | NZ702469A (enExample) |
| PL (2) | PL3266456T3 (enExample) |
| PT (2) | PT3266456T (enExample) |
| RU (1) | RU2663450C2 (enExample) |
| SI (2) | SI3266456T1 (enExample) |
| TW (3) | TWI630924B (enExample) |
| WO (1) | WO2013188586A1 (enExample) |
| ZA (1) | ZA201408804B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2424792C2 (ru) | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| JP6758195B2 (ja) * | 2014-01-14 | 2020-09-23 | ネクター セラピューティクス | 併用ベースの治療方法 |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| AU2015360761B2 (en) * | 2014-12-09 | 2021-05-20 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
| TW201701880A (zh) * | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| AU2016309002B2 (en) * | 2015-08-20 | 2021-07-29 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment |
| ES2826826T3 (es) * | 2015-08-21 | 2021-05-19 | Ipsen Biopharm Ltd | Combinación farmacéutica que comprende irinotecán liposómico, oxaliplatino, 5-fluorouracilo y leucovorina para el tratamiento del cáncer pancreático metastático |
| US10894044B2 (en) | 2015-09-16 | 2021-01-19 | Board Of Regents, The University Of Texas System | Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer |
| EP4647126A2 (en) | 2015-10-16 | 2025-11-12 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| WO2017172678A1 (en) * | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| CA3023743A1 (en) * | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| CN110402163A (zh) * | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| IL282317B2 (en) | 2018-10-17 | 2024-04-01 | Biolinerx Ltd | Treatment of metastatic pancreatic adenocarcinoma |
| WO2020148744A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| EP3911353A1 (en) * | 2019-01-17 | 2021-11-24 | BioLineRx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| EP4087535A1 (en) * | 2020-01-10 | 2022-11-16 | Tyndall Formulation Services, LLC | Formulations of sn-38 with poly(amino acid) block polymers |
| US11286344B2 (en) | 2020-01-10 | 2022-03-29 | Tyndall Formulation Services, LLC | Polymer excipients for drug delivery applications |
| EP4087545A1 (en) | 2020-01-10 | 2022-11-16 | R-Pharm US Operating LLC | Compositions of ixabepilone |
| JP2024536275A (ja) * | 2021-10-03 | 2024-10-04 | システィミューン， インク． | がんを治療する方法及びその医薬組成物 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2628659A (en) * | 1951-01-17 | 1953-02-17 | Charles R Carpenter | Convertible furniture article |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
| US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
| CA2269758C (en) | 1996-10-22 | 2008-01-08 | Hermes Biosciences, Inc. | Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| JP2002527466A (ja) | 1998-09-16 | 2002-08-27 | アルザ・コーポレーション | リポソーム−閉込めトポイソメラーゼ阻害剤 |
| US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| AU4564200A (en) | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| JP4786105B2 (ja) | 2000-02-04 | 2011-10-05 | リポクセン テクノロジーズ リミテッド | リポソーム |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| EP1286671B1 (en) | 2000-05-15 | 2006-04-05 | Celgene Corporation | Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan |
| AU2001270413A1 (en) | 2000-06-30 | 2002-01-14 | Inex Pharmaceuticals Corporation | Improved liposomal camptothecins and uses thereof |
| TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
| JP2004525138A (ja) | 2001-03-26 | 2004-08-19 | アルザ・コーポレーシヨン | 治療剤の改良された細胞内送達のためのリポソーム組成物 |
| US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
| WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| EP1438050A2 (en) | 2001-07-23 | 2004-07-21 | Epidauros Biotechnologie AG | Irinotecan for treatment of cancer |
| US20030077833A1 (en) * | 2001-09-07 | 2003-04-24 | Queen's University At Kingston | Diagnositc methods for determining susceptibility to convulsive conditions |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| ITBO20010610A1 (it) | 2001-10-05 | 2003-04-05 | Haworth S P A | Dispositivo per la connessione di gambe ad elementi di arredamento, ed elemento di arredamento comprendente tale dispositivo |
| EP1509203B1 (en) | 2002-05-15 | 2016-04-13 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| WO2003101474A1 (en) | 2002-05-31 | 2003-12-11 | Transmolecular, Inc. | Combination chemotherapy with chlorotoxin |
| WO2004035032A2 (en) | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
| KR20180132969A (ko) | 2003-05-30 | 2018-12-12 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체를 사용한 치료 |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| RU2424792C2 (ru) | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| EP1752150B1 (en) | 2004-06-01 | 2016-08-31 | Kabushiki Kaisha Yakult Honsha | Irinotecan preparation |
| NZ551355A (en) * | 2004-06-03 | 2009-09-25 | Hoffmann La Roche | Treatment of cancer with irinotecan (CPT-11) and erlotinib |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US7842676B2 (en) | 2005-10-25 | 2010-11-30 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
| EP1954286A2 (en) * | 2005-11-10 | 2008-08-13 | SmithKline Beecham Corporation | Inhibitors of akt activity |
| EP1976485A4 (en) * | 2005-12-22 | 2011-10-26 | Celator Pharmaceuticals Inc | LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF |
| EP2329818A1 (en) | 2006-01-17 | 2011-06-08 | Abbott Laboratories | Combination therapy with PARP inhibitors |
| CA2647297A1 (en) | 2006-03-16 | 2007-09-27 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
| WO2008066136A1 (fr) * | 2006-11-30 | 2008-06-05 | Arkray, Inc. | Ensemble d'amorces pour l'amplification du gène ugt1a1, réactif pour l'amplification du gène ugt1a1 comprenant cet ensemble d'amorces, et utilisation de cet ensemble d'amorces |
| CN101674846B (zh) | 2007-02-16 | 2014-07-02 | 梅里麦克制药股份有限公司 | ErbB3抗体及其用途 |
| US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
| EP2187869B1 (en) | 2007-08-17 | 2015-10-14 | Celator Pharmaceuticals, Inc. | Improved platinum drug formulations |
| AU2008303466A1 (en) * | 2007-09-28 | 2009-04-02 | Universitatsspital Basel | Immunoliposomes for treatment of cancer |
| JP2011503071A (ja) | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる子宮がん及び卵巣がんの治療 |
| AU2008333786A1 (en) | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors |
| TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| CA2718918A1 (en) | 2008-03-25 | 2009-11-26 | Schering Corporation | Methods for treating or preventing colorectal cancer |
| US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
| AU2009234253C1 (en) | 2008-04-11 | 2015-05-07 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| AU2008362109B2 (en) * | 2008-09-26 | 2015-08-27 | Institut De Cancerologie De L'ouest | Individual 5-fluorouracile dose optimization in FOLFIRI treatment |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| WO2010125462A2 (en) | 2009-05-01 | 2010-11-04 | Oncozyme Pharma Inc. | Pentamidine combinations for treating cancer |
| US20120282325A1 (en) | 2009-12-03 | 2012-11-08 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Liposome of irinotecan or its hydrochloride and preparation method thereof |
| MX347225B (es) | 2010-06-04 | 2017-04-19 | Abraxis Bioscience Llc * | Metodos de tratamiento contra el cancer pancreatico. |
| JP2013531069A (ja) | 2010-07-19 | 2013-08-01 | バイパー サイエンシズ，インコーポレイティド | ４−ヨード−３−ニトロベンズアミド及びイリノテカンを用いる転移性乳癌の治療方法 |
| MX349662B (es) | 2010-07-22 | 2017-08-08 | Univ California | Anticuerpos de antigenos antitumorales y metodos de uso. |
| WO2012031293A1 (en) | 2010-09-03 | 2012-03-08 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of cancer |
| AU2011338487B2 (en) | 2010-12-06 | 2016-12-22 | Merrimack Pharmaceuticals, Inc. | Dosage and administration for preventing cardiotoxicity in treatment with ErbB2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents |
| US9226984B2 (en) | 2010-12-14 | 2016-01-05 | Technical University of Denmark and Rigshospitalet | Entrapment of radionuclides in nanoparticle compositions |
| EP2675918B1 (en) | 2011-02-15 | 2017-11-08 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| HUE034276T2 (en) | 2011-04-19 | 2018-02-28 | Merrimack Pharmaceuticals Inc | Bispecific anti-IGF-1R and anti-ErbB3 antibodies |
| JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| AU2013201584A1 (en) * | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
| US9511155B2 (en) | 2012-04-17 | 2016-12-06 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| WO2014113167A1 (en) | 2012-12-14 | 2014-07-24 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
| KR101848131B1 (ko) | 2013-03-27 | 2018-04-11 | 다이호야쿠힌고교 가부시키가이샤 | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 |
| JP2016529284A (ja) | 2013-08-27 | 2016-09-23 | ノースイースタン ユニバーシティ | ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法 |
| WO2015061592A1 (en) | 2013-10-23 | 2015-04-30 | Merrimack Pharmaceuticals, Inc. | Liposomes for non-invasive imaging and drug delivery |
| AU2015360761B2 (en) | 2014-12-09 | 2021-05-20 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
| TW201701880A (zh) | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
| AU2016309002B2 (en) | 2015-08-20 | 2021-07-29 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment |
| ES2826826T3 (es) | 2015-08-21 | 2021-05-19 | Ipsen Biopharm Ltd | Combinación farmacéutica que comprende irinotecán liposómico, oxaliplatino, 5-fluorouracilo y leucovorina para el tratamiento del cáncer pancreático metastático |
| EP4647126A2 (en) | 2015-10-16 | 2025-11-12 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
| WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| CA3023743A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
-
2013
- 2013-04-08 AU AU2013202947A patent/AU2013202947B2/en active Active
- 2013-06-11 TW TW102120630A patent/TWI630924B/zh active
- 2013-06-11 TW TW108132921A patent/TWI729492B/zh active
- 2013-06-11 TW TW107116721A patent/TW201831168A/zh unknown
- 2013-06-12 EP EP17169098.5A patent/EP3266456B1/en active Active
- 2013-06-12 ES ES17169098T patent/ES2880089T3/es active Active
- 2013-06-12 RU RU2015100529A patent/RU2663450C2/ru active
- 2013-06-12 PT PT171690985T patent/PT3266456T/pt unknown
- 2013-06-12 CN CN201380036765.4A patent/CN104717961A/zh active Pending
- 2013-06-12 BR BR112014031088A patent/BR112014031088A8/pt not_active Application Discontinuation
- 2013-06-12 ES ES13731230.2T patent/ES2632915T3/es active Active
- 2013-06-12 MX MX2014015391A patent/MX376937B/es active IP Right Grant
- 2013-06-12 JP JP2015517405A patent/JP6310911B2/ja active Active
- 2013-06-12 WO PCT/US2013/045495 patent/WO2013188586A1/en not_active Ceased
- 2013-06-12 PT PT137312302T patent/PT2861210T/pt unknown
- 2013-06-12 DK DK17169098.5T patent/DK3266456T3/da active
- 2013-06-12 NZ NZ702469A patent/NZ702469A/en unknown
- 2013-06-12 CN CN201910188153.6A patent/CN110051631A/zh active Pending
- 2013-06-12 SI SI201331912T patent/SI3266456T1/sl unknown
- 2013-06-12 EP EP21171689.9A patent/EP3919048B1/en active Active
- 2013-06-12 SI SI201330697T patent/SI2861210T1/sl unknown
- 2013-06-12 KR KR1020157000450A patent/KR101776808B1/ko active Active
- 2013-06-12 PL PL17169098T patent/PL3266456T3/pl unknown
- 2013-06-12 IN IN11099DEN2014 patent/IN2014DN11099A/en unknown
- 2013-06-12 DK DK13731230.2T patent/DK2861210T3/en active
- 2013-06-12 CA CA2875824A patent/CA2875824C/en active Active
- 2013-06-12 KR KR1020177024678A patent/KR101997206B1/ko active Active
- 2013-06-12 EP EP13731230.2A patent/EP2861210B1/en not_active Revoked
- 2013-06-12 IL IL294886A patent/IL294886A/en unknown
- 2013-06-12 AU AU2013274287A patent/AU2013274287B2/en active Active
- 2013-06-12 KR KR1020197018996A patent/KR20190107010A/ko not_active Withdrawn
- 2013-06-12 US US14/406,776 patent/US9452162B2/en active Active
- 2013-06-12 IL IL235937A patent/IL235937B/en unknown
- 2013-06-12 PL PL13731230T patent/PL2861210T3/pl unknown
-
2014
- 2014-12-02 ZA ZA2014/08804A patent/ZA201408804B/en unknown
-
2015
- 2015-07-29 US US14/812,950 patent/US9339497B2/en active Active
- 2015-09-03 US US14/844,500 patent/US9364473B2/en active Active
- 2015-09-11 US US14/851,111 patent/US9492442B2/en active Active
-
2016
- 2016-03-03 US US15/059,640 patent/US20160228428A1/en not_active Abandoned
- 2016-11-02 US US15/341,377 patent/US20170065578A1/en not_active Abandoned
-
2017
- 2017-06-08 JP JP2017113465A patent/JP2017149783A/ja not_active Withdrawn
- 2017-07-18 US US15/652,513 patent/US20170368056A1/en not_active Abandoned
-
2018
- 2018-03-19 AU AU2018201942A patent/AU2018201942B2/en active Active
- 2018-06-19 US US16/012,351 patent/US10980795B2/en active Active
-
2019
- 2019-05-07 JP JP2019087488A patent/JP6857210B2/ja active Active
-
2021
- 2021-03-17 US US17/204,278 patent/US20220096458A1/en not_active Abandoned
-
2023
- 2023-07-20 IL IL304631A patent/IL304631A/en unknown
-
2024
- 2024-03-22 US US18/613,609 patent/US20240226090A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2880089T3 (es) | Combinaciones de irinotecán liposomal, 5-FU y leucovorina para el tratamiento del cáncer pancreático | |
| RU2808427C2 (ru) | Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомальный иринотекан | |
| HK1248608B (en) | Combinations of liposomal irinotecan, 5-fu and leucovorin for the treatment of pancreatic cancer | |
| HK1209627B (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |